 BOTHELL, Wash., June 14, 2021 GLOBE NEWSWIRE -- Cocrystal Pharma, Inc. Nasdaq: COCP Cocrystal or the Company, a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces that its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2 and two prominent SARS-CoV-2 variants. 